Management
Team
Team
Martin Babler, President and Chief Executive Officer
Martin Babler is President and Chief Executive Officer of Talima Therapeutics, Inc, a position he has held since December of 2007. From 1998 to 2006 he worked at Genentech where he served as Vice President of Immunology Sales and Marketing, Senior Director of Commercial Development and Director of Cardiovascular Marketing. Prior to joining Genentech, Mr. Babler held various roles of increasing responsibility in sales, sales management, marketing and business development with Eli Lilly and Company. Mr. Babler is a faculty member of the BioExec Institute, a BioPharma Executive Education series at the Haas School of Business and he is a director of Infinity Pharmaceuticals. Mr. Babler holds a degree in Pharmacy from the ETH in Zurich, Switzerland and has attended the Executive Development Program at Kellogg Graduate School of Management.
Paul Denton, Chief Financial Officer
As Chief Financial Officer, Paul is chartered with driving the company’s financial operations, accounting and reporting, human resources, overseeing business operations and the Company’s relationship with the financial community. He brings over 20 years of leadership experience to Talima from a wide diversity of industries and positions.
Paul has held executive management positions with numerous start-up and emerging growth companies in Silicon Valley. Through his expertise in financial management and business operations coupled with his strong leadership skills, he's helped these companies take their business to the next level. Paul also held management positions at Booz Allen and Hamilton and Exxon/Esso Petroleum Company. More recently Paul was CFO at Determina and COO/CFO at Andale. Paul has a MBA from Stanford University and a BS with Honors in Chemical Engineering from University of Birmingham, UK.
Edward F. Schnipper, M.D., Chief Medical Officer
Dr. Schnipper is acting Chief Medical Officer. Dr. Schnipper has over 20 years of experience in clinical development and management in the Pharmaceutical Industry. Recently he has been president of ProJeX and CMO of Novacea. Prior to that he was CEO of Cellgate and VP of Clinical at Alza. He has been involved in numerous clinical trials and been responsible for multiple IND’s and NDA’s. He began his career in large Pharma at Hoffmann LaRoche.
Dr. Schnipper has an MD degree from Georgetown University and did a hematology fellowship at NYU and an oncology fellowship at Memorial Sloan Kettering Cancer Center.
